This difference is likely due to the higher proportion of patients in the chemotherapy group receiving Paclitaxel and/or Docetaxel (35.1% in the chemotherapy alone group compared to 5.9% in the apatinib combination chemotherapy group, p = 0.002) (Table 2).The most prevalent non-hematologic toxicities were hand-foot syndrome (35.3%), proteinuria (26.5%), hypertension (61.8%), increased alanine aminotransferase (26.5%), and fatigue (35.3%). Here, GPT is linked to Hand-foot syndrome.